Blood Pressure最新文献

{"title":"Cost-effectiveness analysis of radiofrequency renal denervation for uncontrolled hypertension in Sweden.","authors":"T Kahan, M L Johansen, A M Ryschon, K N Cao, M D Kolovetsios, P Lindgren, J B Pietzsch","doi":"10.1080/08037051.2025.2487583","DOIUrl":"10.1080/08037051.2025.2487583","url":null,"abstract":"<p><strong>Introduction: </strong>Radiofrequency renal denervation (RF RDN) is a catheter-based therapy for uncontrolled hypertension. This model-based analysis examined the cost-effectiveness of RF RDN in Sweden.</p><p><strong>Methods: </strong>Clinical events, costs, quality-adjusted life-years (QALYs) were projected over 10-year and lifetime horizons using a decision-analytic Markov model. Primary health states, included hypertension alone, myocardial infarction (MI), stroke, other symptomatic coronary heart disease (CHD), heart failure (HF), end-stage renal disease (ESRD), and death. Health state transitions were informed by multivariate risk equations. Clinical evidence from the SPYRAL HTN-ON MED trial informed the treatment effect modelled (-4.9 mmHg reduction in office systolic blood pressure (SBP) vs. sham). The base case was conducted from the Swedish healthcare payer perspective. The primary outcome was the incremental cost-effectiveness ratio (ICER),RF RDN vs. standard of care (SoC), evaluated against an assumed willingness-to-pay threshold of SEK 500,000 per QALY gained. Extensive sensitivity analyses were performed.</p><p><strong>Results: </strong>At 10-years, the relative risks with RF RDN were 0.80 for stroke, 0.88 for MI, 0.89 for CHD, 0.72 for HF, 0.96 for ESRD, 0.86 for cardiovascular death and 0.93 for all-cause death. Over lifetime, RF RDN led to incremental costs of SEK 63,136 (total costs SEK 497,498 vs. SEK 434,362) and incremental QALY gain of 0.45 (14.79 vs. 14.34), yielding an ICER of SEK 139,280 per QALY gained. RF RDN was cost-effective across all scenarios and sensitivity analyses.</p><p><strong>Conclusion: </strong>Model projections suggest RF RDN to be a cost-effective therapy for uncontrolled including resistant hypertension in Sweden based on contemporary clinical evidence.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"2487583"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750063","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical characterization of blood pressure phenotypes: the BP phenotype score.","authors":"Maha A Al-Mohaissen, Maisa A Al Zohaifi, Terry Lee, Nada A Almalki, Hend Aleiban, Rabah A Al-Mehisen","doi":"10.1080/08037051.2025.2486284","DOIUrl":"10.1080/08037051.2025.2486284","url":null,"abstract":"<p><strong>Background: </strong>Evidence has linked blood pressure (BP) phenotypes with certain clinical, psychosocial, and occupational features, and characteristic BP variability.</p><p><strong>Objective: </strong>We aimed to evaluate the value of a diagnostic score developed from these characteristics in predicting BP phenotypes, when used in a manner comparable to the application of out-of-office techniques.</p><p><strong>Methods: </strong>Adult patients with no prior diagnosis of hypertension attending their office appointments, were prospectively enrolled. Their clinical, psychosocial, and occupational data were collected. 3-consecutive pre-appointment BP measurements, and BP variability with standing and the 6-minute walk test (6MWT) were obtained. All participants underwent 24-hour BP monitoring which was paired with office BP as the reference standard for BP phenotyping. Two scores were developed from the variables selected using linear regression analysis to differentiate between masked hypertension (MH) and normotension, and sustained hypertension (SH) and white coat hypertension (WCH).</p><p><strong>Results: </strong>In total 212 participants completed the study. Among office-normotensives, a score of 7 (calculated from, variables (points): dyslipidemia (3), irritable bowel syndrome (IBS) (3), orthostatic increase in SBP >5 mmHg (1), SBP increase >10 after 6MWT (1), and BP ≥130/80 after 6MWT (3)) identified MH with 90% sensitivity, 86% specificity, 70% positive predictive value (PPV), and 96% negative predictive value (NPV). Conversely, among office-hypertensives, a score of 6 (male sex (2), no IBS (2), ≥3 metabolic syndrome criteria (3), obesity (3), standing BP ≥140/90 (3), BP ≥140/90 after 6MWT (1)) identified SH with 82% sensitivity, 78% specificity, 90% PPV, and 64% NPV.</p><p><strong>Conclusions: </strong>BP phenotypes correspond to distinct clinical phenotypes and can be predicted with acceptable sensitivity and specificity using BP phenotype scores. This novel approach to BP phenotyping provides an accessible addition, not a replacement, to available out-of-office techniques, particularly useful for screening for MH, and to support office diagnosis of SH when out-of-office measures are unavailable or not tolerated.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"2486284"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Non-debatable issues in defining blood pressure targets for hypertension - Editorial.","authors":"Brent M Egan, Sverre E Kjeldsen, Krzysztof Narkiewicz, Reinhold Kreutz, Michel Burnier, Giuseppe Mancia","doi":"10.1080/08037051.2025.2544721","DOIUrl":"10.1080/08037051.2025.2544721","url":null,"abstract":"","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"2544721"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The shifting landscape of hypertension in China (2002-2019): key epidemiological insights to catalyze precision cardiovascular protection and universal health coverage.","authors":"Zilin Zhao, Fei Xu, Hejia Wan","doi":"10.1080/08037051.2025.2552725","DOIUrl":"https://doi.org/10.1080/08037051.2025.2552725","url":null,"abstract":"","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"34 1","pages":"2552725"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144941278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"On-treatment systolic blood pressure and preserved kidney function in hypertensive patients with proteinuria. The VALUE Trial.","authors":"Eirik Olsen, Julian E Mariampillai, Roland E Schmieder, Kenneth Jamerson, Camilla L Søraas, Giuseppe Mancia, Maria H Mehlum, Knut Liestøl, Anne C K Larstorp, Lene V Halvorsen, Bård Waldum-Grevbo, Rune Mo, Sverre E Kjeldsen, Michael A Weber","doi":"10.1080/08037051.2025.2544715","DOIUrl":"10.1080/08037051.2025.2544715","url":null,"abstract":"<p><strong>Aims: </strong>We investigated on-treatment systolic BP (SBP) <130, 130-139 and ≥140 mmHg related to nephroprotection in 3065 patients with proteinuria and 10,738 patients without proteinuria in the VALUE Trial.</p><p><strong>Method and results: </strong>Worsened kidney function (WKF) was ≥50% increase in serum creatinine, and end-stage kidney disease (ESKD) was dialysis/transplantation. Cox proportional hazards models were adjusted for covariates in the on-treatment SBP groups. Lower SBP was significantly related to less WKF (<i>p</i> < .001) in patients <i>with proteinuria</i>, both at <130 mmHg (<i>n</i> = 14/529, 2.6%) and 130-139 mmHg (<i>n</i> = 46/1176, 3.9%) compared to ≥140 mmHg (<i>n</i> = 145/1358, 10.7%). None of the 532 patients with proteinuria had ESKD at <130 mmHg, and only 11/1194 (0.9%) at 130-139 mmHg (<i>p</i> = .098) compared to 39/1339 (2.9%) at SBP ≥ 140 mmHg. In patients <i>without proteinuria</i> the relation between lower SBP and WKF was not significant (<i>p</i> = .23) at <130 mmHg (<i>n</i> = 24/1927, 1.2%) but significant (<i>p</i> = .04) at 130-139 mmHg (<i>n</i> = 74/4611, 1.6%) compared to SBP ≥ 140 mmHg (<i>n</i> = 117/4199, 2.8%). ESKD was 0.2%, 0.2% and 0.4% in the SBP groups, respectively. WKF fell from 12.1% in Q1 (highest SBP quartile) to 6.1% in Q2 (<i>p</i> = .023), 4.2% in Q3 (<i>p</i> = .006) and 2.8% in Q4 (<i>p</i> < .001) in patients <i>with proteinuria</i> and ESKD from 3.5% (Q1) to 1.6% (Q2) (<i>p</i> = .13), 0.7% (Q3) (<i>p</i> = .027) and 0.1% in Q4 (<i>p</i> = .009). In the patients <i>without proteinuria</i>, neither WKF nor ESKD showed statistically significant changes between SBP quartiles.</p><p><strong>Conclusions: </strong>Our data suggest that, compared to SBP ≥ 140 mmHg, on-treatment SBP <130 and 130-139 mmHg were strongly related to nephroprotection in hypertensive patients with proteinuria.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"2544715"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144788200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"OPTIHEART: determinants and prognostic importance of optimal medical treatment in patients with heart failure with reduced ejection fraction discharged from a heart failure clinic from 2018 to 2020.","authors":"Alaa Sharfo, Astrid Lahn Sørensen, Emil Eik Nielsen, Ilan Esra Raymond, Anne Merete Boas Soja, Michael Hecht Olsen","doi":"10.1080/08037051.2025.2481229","DOIUrl":"10.1080/08037051.2025.2481229","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) is an increasing health problem globally. Profound sex-related differences have been observed regarding the cause, treatment, and prognosis of HF.</p><p><strong>Aim: </strong>To assess baseline predictors for achieving optimal medical treatment (OMT) and the prognostic importance of OMT for male and female patients who have attended a HF clinical program (HFCP).</p><p><strong>Methods: </strong>OPTIHEART was a retrospective study that included 870 consecutive patients with left ventricular ejection fraction (LVEF)≤40% discharged from HFCP in 2018, 2019 or 2020 and followed in registers for a mean of 1083(SD 11.3) days. OMT was defined as receiving an angiotensin-converting-enzyme-inhibitor (ACEi), angiotensin-receptor blocker (ARB) or angiotensin-II-receptor blocker and nephrylisin-inhibitor (ARNI) AND a betablocker (BB) both in doses ≥ 50% of target doses.</p><p><strong>Results: </strong>Achieving OMT was associated with male sex (OR: 2.05 95%CI 1.44-2.97; <i>p</i> < 0.0001) independently of younger age, higher diastolic blood pressure (DBP), and lower creatinine. A lower rate of 5-point MACE was associated with achieved OMT (HR: 0.67 95%CI 0.50-0.90; <i>p</i> = 0.007) independently of female sex (HR: 0.64 95%CI 0.48-0.84; <i>p</i> = 0.002), younger age, never smoking and NYHA ≤ 2. The beneficial effect of OMT was insignificantly more pronounced in patients with male sex, older age, higher creatinine, lower DBP, and body mass index ≤25kg/m².</p><p><strong>Conclusion: </strong>OMT was more frequently achieved in patients with male sex independently of age, DBP, and creatinine. Achieving OMT was associated with less 5-point MACE independently of female sex, younger age, never smoking and NYHA ≤ 2.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"2481229"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143656073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence, awareness and therapeutic control of hypertension in Belgium: an opportunistic screening of nearly 6,000 participants during the May Measurement Month campaigns 2017-23.","authors":"D De Bacquer, S Bayet, A Bondue, F Brohée, S Brouwers, A Carlier, M Chabot, P Delmotte, B Falque, H Heuten, J Huart, J M Krzesinski, A Persu, T Robberechts, T Vanassche, E Van Der Beken, Ph Van de Borne, P Van der Niepen, B Van Nieuwenhuyse, J Vanparys, T De Backer","doi":"10.1080/08037051.2025.2501956","DOIUrl":"https://doi.org/10.1080/08037051.2025.2501956","url":null,"abstract":"<p><strong>Background: </strong>The May Measurement Month (MMM) initiative is an annual global screening campaign started in 2017 by the International Society of Hypertension highlighting the importance of regular measurements of blood pressure (BP). Here we report on the results of the MMM campaign done in Belgium during the month of May in 2017, 2018, 2019, 2022 and 2023.</p><p><strong>Methods: </strong>Participants ≥18 years were recruited through opportunistic sampling in 12 sites (mostly hospital entrances) across Belgium. Apart from standardised BP recordings by trained staff, data were collected on demographics, lifestyle factors and comorbidities. Hypertension was defined as raised BP (systolic BP ≥140 mmHg and/or diastolic BP ≥90 mmHg) and/or taking antihypertensive medication.</p><p><strong>Results: </strong>Data were collected from 5,926 participants aged 51.5 years on average. Mean (SD) systolic and diastolic BP were 125.9 (17.6) mmHg and 79.4 (10.9) mmHg with 25.8% exceeding the 140/90 mmHg threshold. Age-standardised prevalences of hypertension were 45.4% in men and 36.9% in women. Among the 2,468 individuals with hypertension, 78.5% had been previously diagnosed and 1,578 of those with known hypertension, received antihypertensive treatment. Only about half of those being treated (56.3%) did achieve the target of systolic/diastolic BP <140/90 mmHg. Inadequate therapeutic control was independently associated with increasing age and higher body mass index. Untreated hypertension was significantly associated with male sex, age, body mass index and alcohol use.</p><p><strong>Conclusion: </strong>Despite the limited representativeness of the sample, these data suggest that the 'rule of halves' for hypertension no longer holds true in Belgium and that therapeutic control of hypertension is still suboptimal.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":"34 1","pages":"2501956"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143969497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of amlodipine-based therapy on blood pressure time in target range in Chinese adults with primary hypertension: a retrospective study.","authors":"Hongyi Wang, Yuqing Zhang, Jinxiu Lin, Yan Shu, Peili Bu, Zhaohui Wang, Wei Song, Yi Zhang, Wei Yu, Ningling Sun","doi":"10.1080/08037051.2025.2510317","DOIUrl":"10.1080/08037051.2025.2510317","url":null,"abstract":"<p><strong>Background: </strong>Recently, both international and Chinese guidelines have mentioned for the first time that blood pressure (BP) target range is more reasonable and workable than BP target in clinical practice, and time in target range (TTR) could become a potential evaluation indicator for long-term blood pressure management. Until now, there was no research on the long-term effects of antihypertensive treatment on systolic BP (SBP) TTR. The objective, therefore, is to observe the impact of long-acting calcium channel blockers (CCBs) on BP TTR in Chinese patients with hypertension (HTN).</p><p><strong>Methods: </strong>A retrospective observational study was conducted using data from the China Cardiovascular Association Hypertension Centre, including 36,153 adult patients diagnosed with primary HTN and treated with amlodipine-based antihypertensive therapy between 1 January 2018 and 31 December 2022. The primary endpoint was the SBP TTR. Other endpoints included the annual trend of SBP TTR, factors influencing SBP TTR, etc.</p><p><strong>Results: </strong>Results showed an overall SBP TTR was 80.42 ± 21.97%. The SBP TTR at 1, 2 and 3 years of follow-up was 79.49 ± 26.16%, 81.86 ± 25.10% and 82.79 ± 25.77%, respectively, showing a significant difference (<i>p</i> < 0.001). Seven factors were positively correlated with SBP TTR, while three factors were negatively correlated with SBP TTR including heart failure, high baseline SBP level, and high LDL-C level.</p><p><strong>Conclusion: </strong>Long-term and continuous use of amlodipine-based antihypertensive therapy could improve SBP TTR. This finding may relate to the characteristic of amlodipine which is a long-acting drug due to pharmacokinetic properties.</p><p><strong>Trial registration: </strong>Chinese Clinical Trial Registry Identifier: ChiCTR2400090150.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"2510317"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weight loss following gastric bypass increases aldosterone reactivity to orthostatic stress in patients with obesity.","authors":"Joachim Zahnd, Nima Vakilzadeh, Nora Schwotzer, Mariëlle Hendriks-Balk, Styliani Mantziari, Julien Sauser, Marc Maillard, Eric Grouzmann, Lucie Favre, Gregoire Wuerzner","doi":"10.1080/08037051.2025.2555452","DOIUrl":"10.1080/08037051.2025.2555452","url":null,"abstract":"<p><strong>Background: </strong>Weight loss after gastric bypass is associated with blood pressure (BP) reduction. However, the precise role of the sympathetic nervous system (SNS) and renin-angiotensin-aldosterone system (RAAS) in this reduction remains unclear. We investigated the effect of RYGB-induced weight loss on the hemodynamic, hormonal and renal responses to an orthostatic stress induced by lower body negative pressure (LBNP).</p><p><strong>Methods: </strong>We conducted a monocentric study comparing response to LBNP (-30 mbar) in two groups of obese participants the first group underwent RYGB surgery (RYGB group) and the second group received lifestyle counselling (control group). We studied urinary sodium excretion, hemodynamic and hormonal responses before, during and 1 h after orthostatic stress induced by LBNP at three timelines: one month before planned RYGB (intervention group), and 3 and 12 months after the intervention.</p><p><strong>Results: </strong>Thirty-seven adult participants were enrolled: 25 patients (72% women, age: 42.1 ± 10.5 years old, BMI 43.0 ± 5.1 kg/m²) in the RYGB group and 12 in control group (58% women, age: 44.8 ± 13.6 years old, BMI 43.3 ± 5.3 kg/m²). At 12 months, mean weight decreased from 126.3 ± 23.2 kg to 116 ± 20.7 kg in the control group and from 120.9 ± 19.4 kg to 78.6 ± 14.0 kg in the RYGB group (<i>p</i> value < 0.01 between groups). During LBNP, the reduction in urinary sodium excretion (-1.98 mmol/h; CI95%: -3.72 to -0.30, <i>p</i> value = 0.02) and the increase in plasma aldosterone concentration (PAC; +9.94 pg/ml, CI 95%: 0.317-19.569, <i>p</i> value = 0.043) were more pronounced in the RYGB group.</p><p><strong>Conclusions: </strong>Our study suggests that weight loss induced by RYGB increases aldosterone responsiveness to orthostatic stress and enhances the sodium tubular response during orthostatic stress.</p><p><strong>Clinicaltrials.gov id: </strong>NCT02218112.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"2555452"},"PeriodicalIF":2.3,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144941478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"More intensive versus conservative blood pressure lowering after endovascular therapy in stroke: a meta-analysis of randomised controlled trials.","authors":"Ahmed Naji Mansoor, Vatsalya Choudhary, Zain Mohammad Nasser, Muskan Jain, Dhruvikumari Dayanand Sharma, Mateo Jaramillo Villegas, Sujaritha Janarthanam, Muhammad Ayyan, Simran Ravindra Nimal, Huzaifa Ahmad Cheema, Muhammad Ehsan, Muhammad Aemaz Ur Rehman, Abdulqadir Nashwan, Sourbha S Dani","doi":"10.1080/08037051.2025.2475314","DOIUrl":"10.1080/08037051.2025.2475314","url":null,"abstract":"<p><strong>Background: </strong>The optimum systolic blood pressure (BP) after endovascular thrombectomy for acute ischaemic stroke is uncertain. We aimed to perform an updated meta-analysis of randomised controlled trials (RCTs) to evaluate the safety and efficacy of more intensive BP management compared to less intensive BP management.</p><p><strong>Methods: </strong>We searched various electronic databases to retrieve relevant RCTs on the clinical effects of more intensive BP management after endovascular thrombectomy compared to the less intensive management. We calculated odds ratios (ORs) with 95% confidence intervals (CIs) for dichotomous outcomes.</p><p><strong>Results: </strong>Our meta-analysis included four RCTs with a total of 1560 patients. More intensive BP management (<140 mmHg) was associated with a statistically significant decrease in the number of patients showing functional independence (modified Rankin scale [mRS] score = 0-2) at 90 days (OR 0.69; CI = 0.51-0.94). Regarding 90-day mortality, our pooled results showed no statistically significant difference between the two groups (OR 1.21; CI = 0.89-1.65). There was no statistically significant difference between the two groups regarding the incidence of intracerebral haemorrhage (ICH) (OR 1.09; CI = 0.85-1.39) and the incidence of symptomatic intracerebral haemorrhage (sICH) (OR 1.11; CI = 0.75-1.65).</p><p><strong>Conclusion: </strong>According to our meta-analysis, the intensive BP lowering group decreased the number of patients showing functional independence at 90 days. We found no benefit of the intensive lowering of BP on mortality rates and incidence of ICH compared to the conservative BP management. Future large-scale trials should focus on other interventions to improve prognosis in these patients.</p>","PeriodicalId":9000,"journal":{"name":"Blood Pressure","volume":" ","pages":"2475314"},"PeriodicalIF":1.8,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143540047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}